Search

Displaying results 6601 - 6610 of 10000 in total
  1. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  2. Drug

    Disoxaril

    go.drugbank.com/drugs/DB08726
    Experimental

    This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.

  3. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  4. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  5. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  6. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    of the gall bladder). … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.

  7. Drug

    MRx-4DP0004

    go.drugbank.com/drugs/DB15751
    Investigational

    MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

  8. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]

  9. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

  10. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment